Innoskel Announces First Patient Enrolled in Observational Study to Evaluate Children Living with Type II Collagen Disorders
13 juil. 2022 02h00 HE
|
InnoSkel
Innoskel Announces First Patient Enrolled in Observational Study to Evaluate Children Living with Type II Collagen Disorders Study will build a type II collagen disorder observational data set to...
Innoskel Appoints Dr Michel Detheux as Chairman
12 avr. 2022 02h00 HE
|
InnoSkel
Innoskel Appoints Dr Michel Detheux as Chairman Nice, France, 12 April 2022 – Innoskel (the “Company”), a pioneering biotechnology company developing transformative therapies for the unmet needs of...
InnoSkel awarded Innovation Passport by the UK MHRA for the treatment of a rare bone disorder
16 déc. 2021 02h00 HE
|
InnoSkel
InnoSkel awarded Innovation Passport by the UK MHRA for the treatment of a rare bone disorder First step in the recent UK MHRA initiative to accelerate the development and access to innovative...
InnoSkel Appoints Dr Sophie Amsellem-Bosq as Chief Technical Officer
14 déc. 2021 02h00 HE
|
InnoSkel
InnoSkel Appoints Dr Sophie Amsellem-Bosq as Chief Technical Officer Nice, France, 14 December 2021 – InnoSkel (the “Company”), a pioneering platform biotechnology company developing transformative...
Innoskel Founder and CEO, Elvire Gouze, PhD Receives EY Entrepreneur Of The Year™ Southeast France 2021 Award
30 sept. 2021 06h00 HE
|
InnoSkel
Innoskel Founder and CEO, Elvire Gouze, PhD Receives EY Entrepreneur Of The Year™ Southeast France 2021 Award Award recognizes Dr. Gouze’s leadership to transform the treatment paradigm for...
INNOSKEL EXPANDS LEADERSHIP TEAM TO ACCELERATE DEVELOPMENT OF LEAD PROGRAM AND DRIVE PLATFORM INNOVATION
25 mai 2021 02h00 HE
|
InnoSkel
INNOSKEL EXPANDS LEADERSHIP TEAM TO ACCELERATE DEVELOPMENT OF LEAD PROGRAM AND DRIVE PLATFORM INNOVATIONDavid Favre PhD Appointed Chief Scientific Officer and Samantha Parker Appointed Chief Patient...
InnoSkel Launches with €20 Million Series A Financing
14 déc. 2020 01h00 HE
|
InnoSkel
InnoSkel Launches with €20 Million Series A Financing Proceeds to support development and advancement of innovative gene therapies for patients with rare skeletal diseases Founded and led by...